US Oncologist Survey: Optimizing Treatment for Advanced Renal Cell Cancer



Assessment Group

$ 6900

In Stock

Treatment decisions for advanced stages of renal cell cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists’ choices. This series of reports will allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer. 

Primary research for the oncology prescribing data that you are missing, directly from high-prescribing US oncologists: what they prescribe, when, and why. Case highlights include:
  • Older patient with retroperitoneal adenopathy and small lung nodules
  • Anemic patient with extremely high LDH levels
  • Patient with multiple comorbidities including heart and lung disease
  • Patient with one kidney and comorbidities

This report allows you to:

  • Understand what occurs in the oncologist’s office with actual patients
  • Access the most up-to-date prescribing trends and the factors that influence treatment decisions
  • Gain actionable data for developing and improving market strategies
  • Pinpoint the needs of your target audience to capitalize on opportunities that improve the position of your product
  • Design messages to advance brand performance and impact decisions
  • Focus your resources to maximize the effectiveness of your budget